Investors might be interested in how sell-side analysts are viewing shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Taking a peek at the current consensus rating, we can see that the ABR is 2.67. This average rating is provided by Zacks Research. This simplified scale ranges from one to five which translates brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 indicates a consensus Sell rating. In terms of the number of analysts that have the stock pegged as a Buy or Strong Buy, we note that the number is presently 4.
Following all the swirling information about publically traded companies can be quite a task. Every day there may be new pieces of news that emerge about a specific company. The prudent investor is typically able to keep abreast of the information, but most importantly figure out what news is worth paying attention to, and what news should be filtered out. Keeping a sharp eye on earnings reports and fundamental company data can play a big part in picking the right stocks for the portfolio. Once the numbers have been crunched, investors should be able to see things a little bit clearer and know what the general feel for the stock is. Of course there will be stocks that look good after thorough examination but still fail to perform as expected.
Shifting gears, we can see that the current quarter EPS consensus estimate for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) is 0.95. This EPS estimate is using 7 sell-side analysts polled by Zacks Research. For the prior reporting period, the company posted a quarterly EPS of 1.04. As we move through earnings season, all eyes will be on the company to see if they can beat analyst estimates and show improvement from the last quarter. When a company reports actual earnings numbers, the surprise factor can cause a stock price to realize increased activity. Investors and analysts will be closely watching to see how the earnings results impact the stock after the next release. Many investors will decide to be cautious around earnings releases and delay buy/sell moves until after the stock price has steadied.
Viewing some popular support and resistance marks on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX), we can see that the 52-week high is presently $17.77, and the 52-week low is currently $8.51. When the stock is trading near the 52-week high or 52-week low, investors may be on the lookout for a potential break through the level. Looking at recent action, we can see that the stock has been trading near the $17.49 level. Investors may also want to track historical price activity. Over the past 12 weeks, the stock has changed 23.26%. Looking further back to the beginning of the calendar year, we note that shares have moved 20.45%. Over the previous 4 weeks, shares have seen a change of 45.27%. Over the last 5 trading sessions, the stock has moved 6.13%. Investors will be monitoring stock activity over the next few days to try and gauge which way the momentum is shifting.
Wall Street analysts tracking shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) have been closely monitor company activities and fundamentals. They often create research reports to assist with investment decisions. On a consensus basis, analysts have set a target price of $16.85 on the stock. This number may be different from the First Call consensus target estimate. Analysts that routinely cover the company may use different techniques in order to create a future target price. Because of the different methods, price targets may differ greatly from one analyst to another.